Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan-Reference-Cited by-同舟云学术

Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan

Published:2008-11-17 Issue:1 Volume:115 Page:84-93
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Grinblatt David L.,Yu Daohai,Hars Vera,Vardiman James W.,Powell Bayard L.,Nattam Sreenivasa,Silverman Lewis R.,Castro Carlos de,Stone Richard M.,Bloomfield Clara D.,Larson Richard A.,

Funder

National Cancer Institute

CALGB

CALGB Statistical Center

Unknown funding agency

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.23995/fullpdf

Reference27 articles.

1. Proposals for the classification of the myelodysplastic syndromes;Bennett;Br J Haematol,1982

2. The World Health Organization (WHO) classification of the myeloid neoplasms;Vardiman;Blood,2002

3. Myelodysplastic syndromes: a scoring system with prognostic significance;Mufti;Br J Haematol,1985

4. Effect of androgen therapy and anemia on serum erythropoietin levels in patients with aplastic anemia and myelodysplastic syndrome [abstract 1341];Piedras;Blood,1995

5. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial;Negrin;Ann Intern Med,1989

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents;Clinical Lymphoma Myeloma and Leukemia;2015-06

2. Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups;Haematologica;2013-09-01

3. Standard Therapy for Patients With Myelodysplastic Syndromes;Clinical Lymphoma Myeloma and Leukemia;2011-08

4. MODERN PRINCIPLES OF CLASSIFICATION, PROGNOSIS AND TREATMENT OF PRIMARY MYELODYSPLASTIC SYNDROMES;Health and Ecology Issues;2011-03-28

5. Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents;Current Opinion in Hematology;2010-03